Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
76-90 of 474
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
MinuteCE®The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
Neal Ready, MD, PhD
Ticiana Leal, MD
- advertisement
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Jason Starr, DO
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
The Power of Timing: Therapies That Change Outcomes
MinuteCE®The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS
Prithviraj Bose, MD
Applying Clinical Trial Data in mCSPC Care
Project Oncology®Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD
Jahan Aghalar, MD
Ulka Vaishampayan, MD
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP
Bilal Siddiqui, MD